To explore whether targeting C-type (Ca2+-dependent) lectin-type receptors offers a novel immunotherapeutic approach to cancer treatment, our research focused on CLEC10A (CD301) that is expressed by several cell types at strategic stages in the immune pathway, whose activation can lead to immune responses and a good therapeutic outcome [12]. Here, CLEC10A is linked to cancer.